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Few long-term multicenter investigations have evaluat-
ed the relationships between aggregate antimicrobial drug
use in hospitals and bacterial resistance. We measured flu-
oroquinolone use from 1999 through 2003 in a network of
US hospitals. The percentages of fluoroquinolone-resistant
Pseudomonas aeruginosa and methicillin-resistant
Staphylococcus aureus (MRSA) were obtained from yearly
antibiograms at each hospital. Univariate linear regression
showed significant associations between a hospital’s vol-
ume of fluoroquinolone use and percent resistance in most
individual study years (1999–2001 for P. aeruginosa,
1999–2002 for S. aureus). When the method of generalized
estimating equations was used, a population-averaged lon-
gitudinal model incorporating total fluoroquinolone use and
the previous year’s resistance (to account for autocorrela-
tion) did not show a significant effect of fluoroquinolone use
on percent resistance for most drug-organism combina-
tions, except for the relationship between levofloxacin use
and percent MRSA. The ecologic relationship between flu-
oroquinolone use and resistance is complex and requires
further study.
A
ntimicrobial drug resistance in bacterial pathogens is
of national and international concern (1,2). Although
use of antimicrobial agents is accepted as a major driving
force behind the spread of resistance, the nature of this
relationship is complex (3). Two problematic nosocomial
pathogens are Pseudomonas aeruginosa and  Staphy-
lococcus aureus; both often express multidrug resistance.
A number of case-control studies at individual hospitals
have identified fluoroquinolone use as a risk factor for
acquisition of fluoroquinolone-resistant P. aeruginosa and
methicillin-resistant S. aureus (MRSA) (4–8). While out-
comes for individual patients are most important from a
clinical point of view, an ecologic perspective is also use-
ful to assess the relationship of aggregate antimicrobial
drug use to aggregate measures of bacterial resistance.
Ecologic investigations across multiple hospitals have
reported significant correlations between fluoroquinolone
use and percent resistance for MRSA(9) and P. aeruginosa
(10,11). However, these studies have primarily focused on
teaching institutions, used drug expenditure data rather
than hospital billing records as a measure of use, or were
conducted over a limited time span. We measured fluoro-
quinolone use as well as the percentages of MRSAand flu-
oroquinolone-resistant  P. aeruginosa across 24 US
hospitals during a 5-year period. The purpose of this obser-
vational study was to determine if volume of aggregate flu-
oroquinolone use in individual hospitals and bacterial
resistance in individual years and during the entire study
period are associated.
Methods
Participating Hospitals
Hospitals included in this study were participants in the
Surveillance and Control of Pathogens of Epidemiologic
Importance (SCOPE)–MediMedia Information Tech-
nology (MMIT) Antimicrobial Surveillance Network.
MMIT (http://www.mminfotech.com) is a healthcare infor-
matics corporation that extracts drug-use data from hospi-
tal billing records. Data collection for this project began in
1999 with 19 participating hospitals; that number increased
to 48 hospitals in 2003. Of these, 15 hospitals in 1999, 23
hospitals in 2000 and 2001, and 24 hospitals in 2002 and
2003 provided adequate drug-use and microbiology data
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and Health Systems (http://www.aamc.org/members/coth/
start.htm) were designated as teaching hospitals.
Measurement of Hospital Fluoroquinolone Use
Total grams for each fluoroquinolone used during each
year were electronically extracted from individual patient
billing records and aggregated to reflect hospitalwide
usage. The total number of patient days (PD) for the corre-
sponding time period at each hospital was determined from
the sum of individual patient lengths of stay. These data
were used to express normalized antimicrobial drug use in
defined daily doses per 1,000 patient days
(DDD/1,000PD) as recommended by the World Health
Organization (WHO) (http://www.whocc.no/atcddd/). The
DDDs used were levofloxacin 500 mg, moxifloxacin 400
mg, gatifloxacin 400 mg, and ciprofloxacin 1,000 mg.
(Because the MMIT database does not indicate the propor-
tion of intravenous versus oral ciprofloxacin used, we used
the oral DDD for ciprofloxacin of 1,000 mg for all
ciprofloxacin use).
Measurement of Hospital Susceptibility for 
P. aeruginosa and S. aureus
Hospital antibiograms were requested from each partic-
ipating hospital for each study year. To be included in the
analysis, antibiograms must have reported data on organ-
isms from all clinical sites (i.e., systemic and urinary iso-
lates) and all units (including intensive care units).
Ciprofloxacin or levofloxacin susceptibility was used to
determine the percentage of fluoroquinolone-resistant P.
aeruginosa. Oxacillin or nafcillin susceptibility was used
to determine the percentage of MRSA.
Statistical Analysis
Mixed-effects repeated-measures analysis of variance
was used to analyze changes in fluoroquinolone use and
resistance over the study period, and the Tukey HSD (hon-
estly significantly difference) test was used to compare dif-
ferences between individual years. Relationships between
total and individual fluoroquinolone usage and resistance
in target pathogens for each year were determined by uni-
variate linear regression. To analyze the relationship
between fluoroquinolone use and percent resistance over
the course of the study period, the method of generalized
estimating equations (GEE) was used to construct a popu-
lation-averaged longitudinal model (12). Unlike tradition-
al least squares regression, GEE models do not assume that
each observation is statistically independent. Instead, only
observations across units are assumed to be independent
(i.e., the group of observations from the first hospital are
independent from the observations from the second hospi-
tal). Other methods, such as generalized least squares, can
also account for this correlation of observations within a
given unit; however, these methods are based on the
assumption that the correlation structure among observa-
tions from the same unit is correctly specified. The GEE
method provides some protection against this misspecifi-
cation. This protection can be improved by using a modi-
fied sandwich variance estimator to calculate robust
standard errors. The model constructed in the current study
assumed a first-order autoregressive correlation structure
since a 1-year lagged resistance term was used in the
model to control for the prior year’s resistance. GEE meth-
ods also allow data across time points to be analyzed
simultaneously, rather than in a year-by-year fashion.
Therefore, this GEE model represents the longitudinal
change in the outcome in relation to the longitudinal
change in the set of predictor variables using all of the
available data. Ap value <0.05 was considered significant,
and all tests were 2-tailed. Because of the exploratory
nature of this analysis, p values from univariate linear
regressions were not adjusted for multiple testing.
Results
Characteristics of Study Hospitals
Table 1 shows the demographic characteristics of the
study hospitals in the year 2002. Ten hospitals were desig-
nated as teaching hospitals. The location of the hospitals
was predominantly from the East (12 hospitals), with 7
hospitals from the South, 3 from the Midwest, and 2 from
the West. No significant relationships were seen between
resistance in P. aeruginosa or percent MRSA in the year
2002 and any of the demographic characteristics by uni-
variate linear regression (p>0.05 for all comparisons). 
Fluoroquinolone Use
Figure 1 shows changes in the mean of total and indi-
vidual fluoroquinolone use from 1999 through 2003. For
that period, the mean of total fluoroquinolone use
increased from 119.6 ± 45.6 DDD/1,000 PD in 1999 to
150.4 ± 44.4 in 2003 (p = 0.011). These changes were driv-
en by the early increase in fluoroquinolone use, as mean
values were not significantly different in later (2000–2003)
study years (p>0.05, Tukey HSD). Changes in lev-
ofloxacin use during the entire study were also significant
(p = 0.016), but changes in ciprofloxacin use were not (p =
0.186). Fluoroquinolone use in individual hospitals was
significantly correlated with the previous year’s use
(r>0.75 for all years). 
The diversity of use of individual fluoroquinolones in
hospitals changed during the study period. Figure 1 shows
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pitals. The number of hospitals in which a particular fluo-
roquinolone represented most total fluoroquinolone use
also changed. In 1999, levofloxacin use represented >90%
of total fluoroquinolone use in 4 (27%) of 15 hospitals; 1
hospital used >90% ciprofloxacin. In 2003, 8 (33%) of 24
hospitals used >90% levofloxacin while in 7 hospitals
(30%) moxifloxacin and ciprofloxacin combined to
account for >90% of total fluoroquinolone use. The per-
centage of MRSAand fluoroquinolone-resistant P. aerugi-
nosa in 2003 was compared between the 8 hospitals that
predominantly used levofloxacin, the 7 that predominantly
used moxifloxacin and ciprofloxacin, and the remaining 9
hospitals that used a mixture of fluoroquinolones. No sig-
nificant differences in mean percent resistance were found
between the groups (predominant levofloxacin, predomi-
nant moxifloxacin/ciprofloxacin, or neither) for either
pathogen in 2003.
Antimicrobial Drug Resistance
Figure 1 shows the changes in mean percentage resist-
ance for the studied pathogens from 1999 to 2003. Most
hospitals reported the number of isolates tested; at least
100 isolates of S. aureus and 25 isolates of P. aeruginosa
were tested per year. From 1999 to 2003, mean percent flu-
oroquinolone resistance in P. aeruginosa increased from
33.6% to 40.5% (p = 0.001). Mean percent MRSA
increased from 42.1% in 1999 to 50.9% in 2003
(p<0.0001). Correlations between percent resistance in a
given year and percent resistance in the previous year were
high for both pathogens (r>0.8).
Associations between Fluoroquinolone Use and
Percent Resistance in Individual Years
The results of the univariate regressions between fluo-
roquinolone use and resistance are summarized in Table 2.
For  P. aeruginosa, significant relationships occurred
between total fluoroquinolone use and resistance in the
same year for 1999, 2000, and 2001; the relationship had
borderline significance in 2002 (p = 0.0562) and was not
significant in 2003. Total fluoroquinolone use was associ-
ated with percent MRSA in every year except 2003. Table
2 also shows the results of univariate regression with the
individual fluoroquinolones levofloxacin and
ciprofloxacin. Levofloxacin use was a significant predictor
of fluoroquinolone-resistant P. aeruginosa in 1999, 2000,
and 2001. Increasing levofloxacin use was significantly
associated with increased percent MRSA for all study
years except 2003. For ciprofloxacin, a negative slope
(increasing ciprofloxacin use associated with decreased
percent resistance) was observed for most associations
with percent resistant P. aeruginosa and MRSA, but none
of these associations were significant. 
Modeling of Relationship between 
Fluoroquinolone Use and Resistance
Table 3 shows the results of population-averaged GEE
models using data over the study period from 2000 to
2003. The data from 1999 were not used as an outcome
variable because of the lagged resistance term used in the
model. After adjusting for the previous year’s percent
resistance, fluoroquinolone use was generally associated
with a small and nonsignificant effect on percent resistance
in a given year for either pathogen. Levofloxacin did dis-
play a significant contribution to percent resistance in
MRSA; the coefficient of 0.012 suggests that an addition-
al 100 DDD/1,000PD would lead to a 1.2% increase in
percent MRSA over the previous year (p = 0.033). 
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Figure 1. Fluoroquinolone use and resistance over study period.
FQ, fluoroquinolone; Levo, levofloxacin; Cipro, ciprofloxacin; Moxi,
moxifloxacin; Gati, gatifloxacin; DDD/1,000PD, defined daily
doses/1,000 patient-days; FQ-R PSA, fluoroquinolone-resistant
Pseudomonas aeruginosa; MRSA, methicillin-resistant
Staphylococcus aureus.Figure 2 shows the baseline-to-endpoint changes in flu-
oroquinolone use and resistance in P. aeruginosa and
MRSAfor those 9 hospitals with complete data from 1999
to 2003. Fluoroquinolone use increased in 7 hospitals
(arrows pointing to the right), and the percentage of fluo-
roquinolone-resistant  P. aeruginosa increased in 7 and
decreased in 1 (Figure 2A). For the 2 hospitals that
reduced total fluoroquinolone use, percent resistance
increased slightly in both. The percentage of MRSA
increased in 7 hospitals; 5 of these increased fluoro-
quinolone use and 2 decreased use. The percentage of
MRSA decreased in 2 hospitals; both increased quinolone
use during the same period (Figure 2B). 
Discussion
The results of this longitudinal, multicenter study of
fluoroquinolone use and bacterial resistance suggest a
complex relationship between fluoroquinolone use in hos-
pitals and percentage of methicillin-resistant S. aureus and
fluoroquinolone-resistant P. aeruginosa when viewed from
an ecologic level. Fluoroquinolone use was linked to
greater percent resistance in study years by univariate lin-
ear regression. This observation is consistent with the
results of other studies linking fluoroquinolone use to
resistance in these pathogens (4–11), although the path-
ways for selection of resistance differ between the 2
pathogens. Fluoroquinolone resistance in P. aeruginosa is
believed to arise largely from the selection of organisms
with point mutations in the topoisomerase enzymes that
are targets for the fluoroquinolones (13). This hypothesis is
supported by studies demonstrating the emergence of
resistance during therapy with fluoroquinolones (4). For
methicillin-resistant  S. aureus, de novo emergence of
resistance as seen with P. aeruginosa is not a common
event (14); rather, patients are generally believed to
acquire methicillin-resistant strains of S. aureus from the
environment (e.g., through cross-transmission); antimicro-
bial drug use may increase the likelihood of colonization
or amplify the resistant population after colonization (15).
Fluoroquinolones are not active against most methicillin-
resistant isolates (16), providing a selective pressure for
MRSA. While any antimicrobial agent that is not active
against MRSA should increase a patient’s risk for infec-
tion, fluoroquinolones may be particularly likely to do so,
since they have appear to have unique effects on the
expression of MRSA resistance determinants (17) and
fibronectin-binding proteins (18). 
Using a model incorporating the previous year’s
percent resistance as well as fluoroquinolone use and time
over the entire study period, we did not find an additional
effect of total fluoroquinolone use on percent resistance.
Many factors beyond the volume of use of an antimicrobial
agent affect the emergence and spread of antimicrobial
resistance to that drug in the hospital setting. Cross-trans-
mission between patients, acquisition of organisms from
the hospital environment, and the use of different antimi-
crobial agents with linked resistance to the agent under
study are all factors that also affect the number of resistant
isolates in a given hospital (19–21). These factors are dif-
ficult to control for, since quantitative measures of infec-
tion control are lacking, and examining the effects of
multiple antimicrobial agents complicates analysis. We
also did not account for antimicrobial drug use in the com-
munity, which we have previously reported to be associat-
ed with hospital resistance rates (22). Because of the large
number of variables that may influence resistance in the
hospital setting, we would expect hospital fluoroquinolone
use to have at best a modest effect on resistance. The
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fluoroquinolone use is such that substantial changes in flu-
oroquinolone use may be required to affect percent resist-
ance. Thus, a larger sample size, which incorporates more
hospitals over a greater period, may be required to demon-
strate significance, if such effects exist. 
Because percent antimicrobial resistance in a given
period is highly correlated to previous percent resistance
(i.e., the observations are not independent), we incorpo-
rated the previous year’s percent resistance into our longi-
tudinal model. Failing to account for this autocorrelation
may result in spurious associations (23). However, our use
of a 1-year lag period was imposed by the nature of our
data (which was aggregated on a yearly basis) rather than
biologic considerations and may not be the most accurate
method of modeling this relationship. We did not time-lag
the effect of fluoroquinolone use. Monnet et al. used time-
series analysis with autoregressive integrative moving
average (ARIMA) functions to model the changes in per-
cent MRSA in a hospital in Scotland during a 3-year peri-
od (24). Their transfer function model for predicting
percent MRSAused the previous month’s percent MRSA;
the effect of fluoroquinolone use had a 4-month lag in the
effect of changes in fluoroquinolone use on percent
MRSA. No study has specifically examined lag effects
with fluoroquinolone use and fluoroquinolone-resistant P.
aeruginosa, although Lopez-Lozano et al. used a lag peri-
od of 3 and 5 months in percent resistance and a 1-month
lag in ceftazidime use to model the relationship between
ceftazidime use and ceftazidime-resistant gram-negative
bacilli (25). Thus, use of yearly antibiograms may not be
adequate to properly model the relationships between per-
cent resistance in a given year, previous resistance, and
fluoroquinolone use. Future studies should attempt to
attain more detailed data to allow for more flexibility in
modeling the relationship between antimicrobial use and
resistance.
The results of this study raise a number of questions for
further investigation. Why did the association between flu-
oroquinolone use and resistance become weaker in the
later study years? Does this finding represent random fluc-
tuation or an underlying trend? Mean fluoroquinolone use,
after increasing through the first 3 study years, reached a
plateau in the last 2 years (Figure 1). Perhaps associations
with resistance are reflected most strongly when antimi-
crobial drug use is increasing, as was seen in the first 3
study years. The study by Zervos et al. (11) found a signif-
icant association between changes in fluoroquinolone use
and changes in resistance in P. aeruginosa in 10 teaching
hospitals from 1991 to 2000. During this period, fluoro-
quinolone use increased by a mean of 97% in the partici-
pating hospitals; in the present study, the mean increase
during the study period was 23%. Also, the percentage of
resistance among MRSA and P. aeruginosa was relatively
high in all hospitals from the beginning of this study.
Monnet et al., in their study of the impact of antimicrobial
drug use on an outbreak of MRSA in Scotland, observed
that “…antimicrobial drug use was a more important eco-
logic risk factor at the start of the outbreak than once
MRSA had become endemic in the hospital” (24). After
antimicrobial use “drives” resistance to a certain point,
other effects such as cross-transmission may become the
dominant mode of spread. From a scientific standpoint,
this finding suggests that ecologic studies may be more
likely to detect a significant effect when a particular form
of resistance is in its “infancy” (current examples might be
linezolid-resistant  S. aureus or fluoroquinolone-resistant
Streptococcus pneumoniae). From a clinical point of view,
Fluoroquinolone Use and Resistance
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antimicrobial drug use would have the most effect before
resistance becomes widespread.
Also of interest is the effect of individual fluoro-
quinolones on resistance. In our univariate analyses, lev-
ofloxacin use had a much stronger association with
resistance in both pathogens than did use of ciprofloxacin.
Levofloxacin also showed the only significant relationship
(with percent MRSA) among the longitudinal models.
However, the univariate models did not control for prior
resistance levels. Also, the population-averaged modeling
approach results in a pooling of effects across all hospitals,
resulting in some degree of effect attenuation. Indeed, the
estimates from a GEE analysis can sometimes be smaller
than those estimates produced from a corresponding
mixed-effect model (12). This apparent effect attenuation
can be viewed as a trade-off for the reduced vulnerability
to model misspecification, as previously discussed.
Relationships between individual fluoroquinolone use and
resistance should be interpreted with caution, as it is pos-
sible that our study is biased (an unknown confounder that
is causally associated with MRSA or resistant P. aerugi-
nosa occurs more frequently in hospitals that use more lev-
ofloxacin). However, other ecologic studies have found
similar results. At a single teaching institution in an 8-year
period, Mohr et al. observed an association between
increasing levofloxacin use and increasing percent resist-
ance in P. aeruginosa; this effect was not observed for total
fluoroquinolone use or use of other fluoroquinolones (26).
An ecologic study across 174 hospitals across 6 years by
Bhavnani et al. showed that increasing use (measured as
drug expenditures) of levofloxacin and ofloxacin, but not
ciprofloxacin, was associated with increased percent
resistance to ciprofloxacin in P. aeruginosa (10). This eco-
logic effect might arise from a greater in vitro potential for
levofloxacin to select for resistant mutants of P. aerugi-
nosa, as Gilbert and colleagues have observed (27). For
MRSA, a different relationship between fluoroquinolone
use and resistance is relevant, since the emergence of
methicillin resistance during therapy is not of concern.
When viewed from the perspective of selecting for preex-
isting methicillin-resistant, fluoroquinolone-resistant
Staphylococcus aureus from a population that contains
both resistant and susceptible isolates, levofloxacin might
be more likely to select for the preexisting resistant clones
because of its greater activity against the susceptible
organisms. In such a scenario, the proportion of resistant
isolates (percent resistance) may increase, although the
incidence of infections due to resistant bacteria may be rel-
atively stable, as argued by Schwaber et al. (28). Thus,
analysis of incidence rates of isolation of resistant organ-
isms may tell a different story from analysis of percentage
of resistant organisms. We did not determine incidence
rates because some of our study hospitals did not include
the number of organisms isolated on their antibiograms.
Although percent resistance is most likely of concern to a
clinician, the incidence rates determine the overall effect
on impact of resistance from an ecologic perspective.
Future studies should incorporate resistance rates along-
side changes in percent resistance to give the complete pic-
ture of the effect of antimicrobial drug use on resistance.
The differential effects of individual fluoroquinolones on
antimicrobial drug resistance are an important area for
future study, as hospitals manipulate their formularies with
regard to use of individual fluoroquinolones, often for eco-
nomic reasons.
This study has a number of limitations. The study hos-
pitals do not represent a random sample of US hospitals;
further studies are required to determine whether the
results are broadly applicable. We were unable to control
for differences between hospitals in their methods of
antibiogram construction, including methods and reporting
of duplicate isolates, which can affect reported resistance
(29), as well as hospital culturing practices (such as MRSA
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Figure 2. A) Changes in fluoroquinolone use (x axis) and resist-
ance in Pseudomonas aeruginosa (y axis) for 9 hospitals with
complete data, 1999–2003. Origin is median values of fluoro-
quinolone use and resistance in 1999. DDD/1,000 PD, defined
daily doses/1,000 patient-days. FQ-R PSA, fluoroquinolone-resist-
ant  P. aeruginosa; MRSA, methicillin-resistant Staphylococcus
aureus. B) Changes in fluoroquinolone use (x axis) and resistance
(y axis) in S. aureus for 9 hospitals with complete data,
1999–2003.screening). Standardization of methods to report antibi-
ograms has been advocated by the Clinical and Laboratory
Standards Institute (formerly NCCLS), but adherence is
poor (30). We also were not able to control for differences
in infection control measures between hospitals, which are
a likely source of variability in the prevalence of resistant
organisms. Finally, the associations between antimicrobial
drug use and resistance found in ecologic studies such as
this may not always coincide with those observed on an
individual patient level (31). Case-control studies are more
appropriate to quantify the risk associated with antimicro-
bial drug exposure in individual patients.
Our results suggest that the ecologic relationship
between the hospital use of fluoroquinolones and antimi-
crobial resistance in P. aeruginosa and S. aureus is com-
plex. Future studies to better define this relationship would
be worthwhile, in that they would help hospitals determine
where to best invest their resources to reduce the overall
impact of resistance in their institutions, whether through
enhanced infection control measures or more active
antimicrobial stewardship, although both measures are
likely important. Meanwhile, judicious use of fluoro-
quinolones is advocated to prevent the loss of this valuable
therapeutic class.
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